Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Need quick cash? Discover ways to sell items for cash quickly and turn your unused belongings into extra income.
23,920 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Two quantum computing stocks with upside projections have caught the eye of Wall Street. This guide breaks down why t...
Friday Reads offers a disciplined way to close the week. This investing digest blends macro themes, private market pe...
Gas prices keep rising, but major oil companies have not signaled a surge in drilling to curb the pump. Here’s what d...
AMD’s latest earnings reinforce its role in the AI infrastructure wave, setting up this stock biggest bet for May as ...
Upshift launches a new vault platform to deliver instant liquidity for real-world asset redemptions, backed by dedica...
Meta Platforms and Microsoft are turning large AI investments into monetizable products and services, hinting at prof...
Eli Lilly kicked off 2026 with blockbuster sales and higher guidance, reigniting talk of a path to $1800 for Lilly st...
As AI accelerates,Microsoft's split with OPENAI could reshape strategy and investor returns. Learn what this means fo...
Strategy shifted roughly 411 BTC to Coinbase Prime, prompting a fresh look at its cash strategy. The move has revived...
Palantir posted 70% revenue growth in Q4 2025, led by US commercial gains and a robust free cash flow outlook. Trader...
With the housing market cooling, investors are redirecting capital toward durable infrastructure plays. This report e...